





### Issue Seven, Autumn 2016

The National Registry of Rare Kidney Diseases (RaDaR) is a Renal Association initiative designed to pull together information from patients with certain rare kidney diseases. This will give a better understanding of how these illnesses affect people and will also speed up research. Recruitment to RaDaR is now open to all UK renal centres, adult and paediatric.

### Wall of Fame!

We greatly appreciate all the hard work and support that every member of the research teams at our 73 participating hospitals puts into making RaDaR a success. We would like to take this opportunity to 🕹 express particular thanks to the following individuals for their promotion of RaDaR:

- Dr Cath Byrne, Consultant Nephrologist at Nottingham University Hospitals NHS Trust, who has 🖄 personally recruited over 100 patients to RaDaR.
- Hayley King & Faye McMeeken, Senior Research Nurses at Glasgow Clinical Research Facility, who presented a poster on being a nurse PI for RaDaR at NHS Research Scotland's Annual Conference.
- Maria Kokocinska, Rare Diseases Research Coordinator at Birmingham Children's Hospital, who presented posters on RaDaR and the ARPKD Rare Disease Group at the IPNA Congress in Brazil.

# **Data Entry Instructions**

Detailed condition specific data entry instructions for RaDaR are now available.

These can be found under the green cohort tab once a patient has been registered.

The full list of instructions is also available at **bit.ly**/ **RaDaR-Instructions** 

# **Retroperitoneal Fibrosis Patient Study**

The Retroperitoneal Fibrosis Rare Disease Group have set up a patient focused online study to understand the un-met medical needs of patients with this condition.

The survey is open until 31 March 2017 and can be accessed via **bit.ly/RPF-Survey**. All entries are anonymous.

# **Recruitment Target Increase**

The 7,500th patient was recruited to RaDaR in September which is an amazing achievement.

In order to reflect the recent surge in recruitment, we intend to increase our overall NIHR recruitment target from 10,000 to 25,000 patients.

### **Top Recruiters**

73 UK Renal Units are currently recruiting to RaDaR. The table below shows the top five recruiting sites as of 1st November 2016.

Centre	Recruits
Lister Hospital, Stevenage	422
Glasgow Queen Elizabeth	420
Nottingham City Hospital	412
London Royal Free	326
Royal Stoke University Hospital	312



☆

☆











### RaDaR opens to two new conditions

RaDaR has recently opened to two new conditions - Fibromuscular Dysplasia and Fabry Disease.

No additional approvals are needed to recruit these patients.

For further information on all eligible conditions please visit rarerenal.org or e-mail:

Melanie.Dillon@renalregistry.nhs.uk

### **Recruitment Boost**

Recruitment to RaDaR has once again seen a massive increase over the last quarter, with over 750 patients being recruited in October 2016, making it our best recruiting month by far.



### **RaDaR Patient Leaflet and Slide Set**

A new patient-focused leaflet is now available to advertise RaDaR to patients and family members. The leaflet lists the conditions currently eligible for inclusion and explains the benefits for both patients and clinicians in joining RaDaR.

The leaflet can be downloaded from bit.ly/Radar-Patient-Leaflet-2016

Printed copies of the leaflet and other promotional material for RaDaR, including a customisable slide-set, are available on request from Melanie.Dillon@renalregistry.nhs.uk

Please contact us for the latest recruitment figures and statistics if you would like to do a presentation or poster on RaDaR and we would be happy to help.

Oxalosis & Hyperoxaluria Foundation

# Birmingham Children's Hospital NHS

**NHS Foundation Trust** 

# PRIMARY HYPEROXALURIA UK PATIENT DAY SATURDAY 28TH JANUARY 2017 10.300M -3.30pm EDUCATION CENTRE, BIRMINGHAM CHILDREN'S HOSPITAL

#### Welcome

Dr Sally Hulton Consultant Paediatric Nephrologist, Birmingham Children's Hospital

# Welcome from the OHF

Kim Hollander, Executive Director, OHF

# The history of Primary Hyperoxaluria (PH) and understanding how it occurs

Professor Christopher Danpure, Emeritus Professor of Molecular Cell Biology, University College London

# Genes and Primary Hyperoxaluria: understanding the different types and the tests that help make a diagnosis Dr Gill Rumsby

Consultant Biochemist & Clinical Lead, HSL Analytics LLP, University College London

# Managing Primary Hyperoxaluria with medicines

Dr Sally Hulton

### **Understanding dialysis**

Senior Dialysis Sister Birmingham Children's Hospital

### Managing stones with operations – new developments

Urology Department Birmingham Children's Hospital

# Managing Primary Hyperoxaluria with transplants of the liver and kidney – understanding the operation


Dr K Sharif Consultant Transplant Surgeon, Birmingham Children's Hospital


### Long term with Primary Hyperoxaluria: future with transplants and new ideas

Dr G Lipkin Consultant Nephrologist, University Hospital Birmingham

Understanding research studies and what they mean for the future Dr Sally Hulton and Kim Hollander

Registration on the OHF website or: https://www.flipcause.com/secure/cause\_pdetails/OTIxMQ





https://www.eventbrite.co.uk/e/gitelman-and-bartter-syndromes-supportday-tickets-28329952651

> Any queries? Please contact Kathryn Irons by email ki260@medschl.cam.ac.uk or telephone 01223-254605

Full programme to follow in November at:

www.gitelmansyndrome.co.uk & www.rarerenal.org

Supported by



NHS National Institute for Health Research



# **Cambridge Clinical Trials Unit**

The DRINK study is looking to recruit patients with polycystic kidney disease (known as ADPKD or PKD) to take part in a research study to determine how much water to drink. Participants will be randomly assigned to either a daily prescription of high water intake or to continue with their usual drinking practices.

The aims of the study are:

- 1. To determine whether it is possible and safe for people to drink an amount of water large enough to stop the body making a hormone called vasopressin.
- 2. To see whether participants can effectively use a home urine test to measure whether or not they have had the right amount to drink

This study will give us the information we need to design a larger study to see whether drinking the right amount of water can preserve kidney function for longer.

If you are interested in taking part, please contact us:

Telephone: 01223 596471

Email: add-tr.drinktrial@nhs.net

It would be particularly helpful to us to have more than one member of the same family in the study. If you have a relative with PKD, please pass this information to them.

### **Recruitment Update**

The table below shows the recruitment figures and data entry fields for each condition as of 1st November 2016, when there were 8,436 UK patients in RaDaR from 73 Renal Units.

	Current data entry		
Rare Disease Group	Generic	Condition specific	Number of recruits
ADPKD	$\checkmark$	$\checkmark$	1410
ADTKD/FUAN	$\checkmark$	$\checkmark$	82
aHUS	$\checkmark$		100
Alport Syndrome	$\checkmark$	$\checkmark$	344
APRT-D	$\checkmark$		5
ARPKD	$\checkmark$	$\checkmark$	95
Calciphylaxis	$\checkmark$		17
Cystinosis	$\checkmark$		75
Cystinuria	$\checkmark$		216
Dent Disease & Lowe Syndrome	$\checkmark$		38
Fabry Disease	$\checkmark$		Newly Opened
Fibromuscular Dysplasia	$\checkmark$		1
HNF1-B	$\checkmark$	$\checkmark$	40
Stec HUS	$\checkmark$		73
Hyperoxaluria	$\checkmark$		62
Hypokalaemic Alkaloses	$\checkmark$	$\checkmark$	177
IgA Nephropathy	$\checkmark$		908
Membranoproliferative Glomerulonephritis, Dense Deposit Disease and C3 Glomerulopathy	$\checkmark$	$\checkmark$	517
Membranous Nephropathy	$\checkmark$		1032
Nephrotic Syndrome	$\checkmark$	$\checkmark$	1432
Pregnancy & Chronic Kidney Disease	$\checkmark$		174
Pure Red Call Aplasia	$\checkmark$		2
Retroperitoneal Fibrosis	$\checkmark$		34
Vasculitis	$\checkmark$		1342

If you are having problems with recruitment or in getting your site set-up please contact:

Melanie Dillon - melanie.dillon@renalregistry.nhs.uk